In addition, EVO preserves mitochondrial function by increasing the activity of the PGC1α/NRF1/TFAM signaling pathway (Fig. 6D) and inhibits the development of cardiac hypertrophy and fibrosis by attenuating TGFβ/IGFBP7/Col1a1 expression. Here, PPARGC1A is linked to cardiac hypertrophy.